InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: bidrite post# 227837

Tuesday, 07/28/2015 8:34:08 PM

Tuesday, July 28, 2015 8:34:08 PM

Post# of 345694

..a puzzle piece to chase down look at the timing Peregrine started to use the terminology "changing non-responders into responders". During the time that came NOBODY was using that language nor did it seem meaningful. All of a sudden BMS started talking about Opdivo responders & non-responders during ASCO. Now we have trials between the two drugs and an MSK collaboration. Coincidence? I think not. Again check the timing of when we started using the language compared to the rest of the world.



I agree and definitely a nice puzzle piece...




"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News